A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.
“The microbiome is a highly complex and diverse community of microorganisms living in and on the human body,” describes Dr. Kate Markey, Assistant Professor in the Translational Science and ...
Groundbreaking research in The Journal of Molecular Diagnostics shows that analysis of specific patterns of cell-free DNA ...
Cell-free DNA (cfDNA) has emerged as a powerful biomarker for monitoring allograft health and detecting rejection in solid organ transplantation. Since 2022, the Paris Transplant Group-PITOR has ...
Small cell lung cancer (SCLC) remains a challenging cancer type to treat effectively. While patients initially respond to chemotherapy and immunotherapies, the disease almost always returns, often ...
Donor-derived cell-free DNA can aid detection, diagnosis, and monitoring of antibody-mediated rejection after kidney transplantation. Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker ...
Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial Our findings revealed a ...
Researchers from the University of Washington and the University of Utah observed the DNA difference by analyzing fragments derived from human glioblastoma and hepatocellular carcinoma cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback